TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Calcipotriol and Polymorphic Light Eruption

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PLE either by typical history and/or typical histology of lesions and/or positive phototesting results~* Age \> 18 years~Exclusion Criteria:~* Presence of or history of malignant skin tumors~* Dysplastic melanocytic nevus syndrome~* Photosensitive diseases such as porphyria, chronic actinic dermatitis, Xeroderma pigmentosum, basal cell nevus syndrome, and others~* Autoimmune disorders such as Lupus erythematosus or dermatomyositis~* Psychiatric disorders~* Immune deficiency or systemic treatment with steroids and/or other immunosuppressive drugs~* Pregnancy or lactation~* Antinuclear antibodies~* UV exposure in test fields within 8 weeks before study start~* General poor health status~* Severe liver or renal disease, disorders or therapy of the calcium metabolism with vitamin D containing drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, \>=18 years of age;~* rheumatoid arthritis of \>=6 months duration diagnosed according to the revised 1987 ACR criteria;~* DAS28 of \>3.2;~* At screening either ESR \>=28 mm/h or CRP \>=1 mg/dL;~* Having received permitted DMARDs, 1 or more; current DMARD therapy must have been at a stable dose for at least 8 weeks prior to baseline.~Exclusion Criteria:~* major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months following screening;~* functional class IV as identified by the ACR classification of functional status in RA;~* rheumatoid autoimmune disease other than RA;~* prior history of or current inflammatory joint disease other than RA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Thromboangiitis Obliterans (Buerguer's Disease) With Bosentan

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Critical ischemia in any extremity, causing pain at rest or non-healing ischemic ulcers, present for at least four weeks with no evidence of improvement in response to conventional treatment.~Exclusion Criteria:~* Being candidates for surgical or endovascular revascularisation of the extremity studied.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Bosentan (Type: None): Bosentan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-65 years of age;~* chronic hepatitis C, genotype 1.~Exclusion Criteria:~* decompensated liver disease, or impaired liver function;~* presence or history of non-hepatitis C chronic liver disease;~* HBsAg or HIV infection;~* history of cancer within 5 years, other than localized or in situ cancer of the skin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): None
- Cohort B (Type: EXPERIMENTAL): None
- Cohort C (Type: EXPERIMENTAL): None
- Cohort D (Type: EXPERIMENTAL): None
- Cohort E (Type: EXPERIMENTAL): None
- Cohort F (Type: EXPERIMENTAL): None
- Cohort G (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Treated for or diagnosed hypercholesterolemia or have had a high risk with hypercholesterolemia~* LDL-C between 3.36mmol/L and 6.5 mmol/L if not treated with statin or between 2.6mmol/L and 4.14 mmol/L~* Fasting triglyceride less than 4.52mmol/L~Exclusion Criteria:~* History of statin induced myopathy~* Unstable or uncontrolled cardiovascular diseases~* Familial dysbetalipoproteinemia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Rosuvastatin 5mg qd
- 2 (Type: EXPERIMENTAL): Rosuvastatin 10mg qd
- 3 (Type: ACTIVE_COMPARATOR): Atorvastatin 10mg qd

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tramadol Versus Placebo in the Management of Postoperative Pain Following Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* The patient is male or female 18-75 years of age undergoing unilateral first metatarsal bunionectomy surgery~* Willing to give consent and able to understand the study procedures~* Female patients must be of non-childbearing potential or be practicing a highly effective contraception~* The patient must be willing to be housed in a healthcare facility and able to receive parenteral analgesia for at least 72 hours after surgery.~* The patient meets definition of American Society of Anesthesiologists (ASA) Physical Class 1, or 2.~Exclusion Criteria:~* Patient is not expected to receive a continuous infusion nerve block as described in the Post-Op anesthetic procedures protocol~* Patient is undergoing bilateral or revision bunionectomy surgery~* The patient has allergy or hypersensitivity (or is intolerant) to opioids or tramadol The patient has known physical dependence on opioids~* The patient has taken other prior/concurrent chronic medications that have not been at a stable dose for at least 2 weeks prior to screening~* The patient is taking herbal or dietary supplements or medications that are moderate or strong inhibitors of CYP2D6 or CYP3A4 or inducers of CYP3A4~* The patient has taken monoamine oxidase (MAO) inhibitors, trazodone, or cyclobenzaprine within 14 days prior to surgery~* The patient cannot be withdrawn from medications (at least 7 days prior to surgery) that may lower the seizure threshold (e.g. anti-psychotic agents, MAOI inhibitors) or which increase serotonergic tone (e.g. selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, triptans).~* The patient has a history of epilepsy, or is known to be susceptible to seizures~* The patient has a history of Long QT Syndrome or a relative with this condition~* The patient has expressed suicidal ideation or is considered to be at risk of suicide.~* The patient is morbidly obese (body mass index \[BMI\] ≥ 40 kg/m2) or has documented sleep apnea requiring pharmacological or device intervention.~* Clinically significant abnormalities in the judgement of the Investigator~* The patient was administered an investigational product within 30 days prior to Screening.~* The patient has previously participated in a clinical study with AVE-901.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AVE-901 50 mg (Type: ACTIVE_COMPARATOR): None
- AVE-901 25 mg (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of T2DM by standard criteria.~* HbA1c ≥ 7.0 to ≤ 10% at Visit 1.~* Age: ≥ 20 to \< 75 years old at Visit 1.~* BMI ≥ 20 to ≤ 35 kg/m2 at Visit 1.~Exclusion Criteria:~* FPG ≥ 270 mg/dL (≥15 mmol/L) at Visit 1.~* Type 1 diabetes, monogenic diabetes, diabetes resulting from pancreatic injury, or secondary forms of diabetes.~* Significant heart diseases~* Hepatic disorder~Other protocol defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin (LAF237) (Type: EXPERIMENTAL): Patients received vildagliptin (LAF237) 50 mg tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study
- Placebo (Type: PLACEBO_COMPARATOR): In this arm, patients received vildagliptin 50 mg matching placebo tablets twice daily for 12 weeks. Patients continued on a stable dose of long-acting or intermediate-acting or pre-mixed insulin, and metformin if applicable, throughout the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with WHO group I PAH~* Stable patients with NYHA/WHO functional class I or II~* Age \>18~* Treatment for PAH with parenteral prostanoid (IV epoprostenol, IV or SQ treprostinil) for at least 90 days~* Dose of prostanoid \< 20 ng/kg/min~* mPAP \< 40 mmHg and RAP \<12 mmHg on catheterization~* Clinical decision to convert from parenteral prostanoid therapy to inhaled treprostinil therapy~Exclusion Criteria:~* Concomitant underlying medical condition limiting ability to perform exercise~* Addition of new PAH medication within the past 90 days prior to enrollment~* Participation in a clinical study involving an investigational drug or device \< 4 weeks prior to the screening visit~* Any additional contraindications and precautions specified in the package inserts for treprostinil (Tyvaso) not listed above

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Active treatment (Type: EXPERIMENTAL): This is the only arm in the trial. All enrolled subjects will be attempted to transition to inhaled treprostinil. There is no placebo and control arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: ECOLOGIC_OR_COMMUNITY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Key Inclusion Criteria:~* Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis~* Patients who are prescribed Harvoni~Key Exclusion Criteria:~* None~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Harvoni (Type: None): Adult patients with chronic genotype 1 HCV infection with or without compensated cirrhosis who take Harvoni as part of routine clinical care at a participating clinic/hospital.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic evidence of EoE~* Clinical symptoms of EoE including dysphagia~Exclusion Criteria:~* Primary causes of esophageal eosinophilia other than EoE

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- RPC4046 Low Dose (Type: EXPERIMENTAL): intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, low dose
- RPC4046 High Dose (Type: EXPERIMENTAL): intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks, high dose
- Placebo (Type: PLACEBO_COMPARATOR): intravenous (IV) infusion only once at first dose, 2 subcutaneous (SC) injections weekly for 16 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Warnings on Sugar-Sweetened Beverages

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Be 18 years or older~* Be able to read and speak English or Spanish~* Be able to take a computer survey in English or Spanish~* Be the parent or guardian to at least one child between the ages of 2 and 12 who consumed at least one sugar-sweetened beverage in the week prior to taking the screener~Exclusion Criteria:~* Cannot have participated in the investigator's previous study at the convenience store in the past year~* Cannot live in the same household as another enrolled study participant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Sugar-Sweetened Beverage Warning Label (Type: EXPERIMENTAL): None
- Neutral label (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anxiolytic and Analgesic Effects of Melatonin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria part one:~* Patients who are candidates for breast surgery.~* BMI between 18 and 30~* Visible veins in the elbow region~* Fertile women use anti-contraception and have performed a negative pregnancy test~Exclusion Criteria part one:~* Patients, who use daily opioids, benzodiazepines or melatonin~* Patients diagnosed with a psychiatric disorder (defined as in medical treatment)~* Patients with severe physical disease (ASA 3-4)~* Patients with previous or ongoing alcohol or drug abuse~* Patients with liver disease (defined as in medical treatment)~* Patients diagnosed sleep disturbances~* Patients who are unable to cooperate according to the protocol~* Patients with allergy to melatonin~Inclusion Criteria part two:~- Male patients who are candidates for inguinal or umbilical hernia reapir~Exclusion Criteria part two:~* Patients, who use daily opioids, benzodiazepines or melatonin~* Patients diagnosed with a psychiatric disorder (defined as in medical treatment)~* Patients with severe physical disease (ASA 3-4)~* Patients with previous or ongoing alcohol or drug abuse~* Patients with liver disease (defined as in medical treatment)~* Patients diagnosed sleep disturbances~* Patients who are unable to cooperate according to the protocol~* Patients with allergy to melatonin~Withdrawal- and drop-out criteria part 2:~* Patients can withdraw at any time during trial~* Complications during surgery occur that lead to:~  1. Immediate reoperation~ 2. Hospitalization to intensive care unit~* If it is considered in the best interest of the patients physical- and psychological health to withdraw from the trial

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: ACTIVE_COMPARATOR): Melatonin 10 mg, gelatin capsules. Pharmacokinetic study: 10 mg x 2. In the morning before surgery and in the evening after surgery.~Anxiolytic and analgesic study: 10 mg x 4. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.
- Placebo (Type: PLACEBO_COMPARATOR): Gelatin capsules. Anxiolytic and analgesic study. Evening the day before surgery, the morning before surgery, immediately after surgery and the evening after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant either must have ceased lactating at screening; or if still lactating or actively breastfeeding at screening, agreed to temporarily cease giving breastmilk to their infant(s).~* Participant had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I).~* Participant had a HAM-D total score of ≥20 and ≤25 at screening and Day 1 (prior to dosing).~* Participant was ≤ six months postpartum.~* Participant was amenable to intravenous therapy.~Key Exclusion Criteria:~* Active psychosis.~* Attempted suicide associated with index case of postpartum depression.~* Medical history of bipolar disorder.~Note: Other protocol-defined inclusion/exclusion criteria applied.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received an infusion rate equivalent to the 90 micrograms per kilogram per hour (μg/kg/h) group.
- SAGE-547 90 μg/kg/h (Type: EXPERIMENTAL): Participants received a 4-hour dose titration period of 30 μg/kg/h (0 to 4 hours), then 60 μg/kg/h (4 to 24 hours), then 90 μg/kg/h (24 to 52 hours), followed by a taper to 60 μg/kg/h (52 to 56 hours), and 30 μg/kg/h (56 to 60 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Subject must have been diagnosed with stage III or/and stage IV histologically confirmed melanoma \[per American Joint Committee on Cancer (AJCC) staging system\] that is unresectable or metastatic~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Subject has not been treated by systemic anticancer therapy for unresectable or metastatic melanoma~Exclusion Criteria:~* Subjects with active brain metastases or leptomeningeal metastases~* Subjects with ocular melanoma~* Subjects with active, known or suspected autoimmune disease~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV (Type: EXPERIMENTAL): Specified dose on specified days
- Ipilimumab 3 mg/kg IV + Nivolumab 1 mg/kg IV (Type: EXPERIMENTAL): Specified dose on specified days
- Nivolumab 6 mg/kg IV + Ipilimumab 1 mg/kg (Type: EXPERIMENTAL): Specified dose on specified days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Screen to Save: A Colorectal Cancer Educational Intervention

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 50-74 years old~* Attendee at event where educational module is offered

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- Inflatable colon educational module (Type: EXPERIMENTAL): Participants attend a brief educational presentation in an inflatable colon, focused on colorectal cancer prevention and screening. Participants also receive a copy of the study information sheet and may receive written educational materials to take home. Participants complete a pre-test and a post-test to assess changes in knowledge and intention to get screened for colorectal cancer.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete